Cyramza is a biologic drug that is administered by intravenous infusion. It is an angiogenesis inhibitor, and similar to bevacizumab (Avastin), this drug hinders new blood vessel growth so that the blood supply that usually sustains tumor growth is blocked. Cyramza is used with FOLFIRI to treat metastatic colorectal cancer when the cancer continues to progress during or after other treatments.
Common Side Effects
- Loss of Appetite
- Inflammation of the Mouth
- Low white blood cell count (neutropenia)